FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
Epistemonikos ID: e683cae49d40b281a0dd36b42c2c31a5326fe279
First added on: Mar 04, 2026